Panbela begins Phase II trial of type 1 diabetes therapy trial

Panbela Therapeutics has commenced a Phase II clinical trial of CPP-1X-T (Eflornithine tablets) for recent onset type 1 diabetes.

The randomised, double-blind study is conducted in partnership with the Indiana University School of Medicine and funded by global type 1 diabetes research and advocacy organisation JDRF.